ITC Limited Board Recommends Final Dividend of ₹8 Per Share for FY26

ITC Limited has announced its audited financial results for the year ended 31st March, 2026. The Board of Directors has recommended a final dividend of ₹8 per share, bringing the total dividend for the fiscal year to ₹14.50 per share. Additionally, the company has announced the re-appointment of Mr. Hemant Bhargava as an Independent Director and set the date for its 115th Annual General Meeting.

Financial Results Overview

The Board of Directors of ITC Limited approved the audited standalone and consolidated financial results for the quarter and twelve months ended 31st March, 2026. The company has confirmed that its statutory auditors, Messrs. S R B C & CO LLP, have issued reports with an unmodified opinion on these financial statements. All primary financial documents, including the balance sheet and statement of cash flows, have been finalized and approved.

Dividend Payout Details

As part of the company’s commitment to shareholder returns, the Board has recommended a final dividend of ₹8 per share for the financial year ended 31st March, 2026. Combined with the interim dividend of ₹6.50 per share declared in January 2026, shareholders will receive a total dividend of ₹14.50 per share for the full fiscal year. The record date for determining eligibility for the final dividend is set for 27th May, 2026. If approved by members at the upcoming Annual General Meeting, the payment is scheduled to be disbursed between 24th July and 29th July, 2026.

Corporate Governance Updates

The company has scheduled its 115th Annual General Meeting for 23rd July, 2026. Furthermore, the Board has recommended the re-appointment of Mr. Hemant Bhargava as an Independent Director of the Company. This reappointment is for a new term of five years, effective from 20th December, 2026, subject to approval from the company’s members.

Source: BSE

Previous Article

ITC Limited Board Approves Audited Financial Results and Declares Final Dividend

Next Article

Alembic Pharmaceuticals Limited Q4 FY '26 Earnings and Strategic Outlook